The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | ELARA: tisagenlecleucel in patients with relapsed/refractory follicular lymphoma
Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, touches on the Phase II ELARA trial which looks at the efficacy and safety of tisagenlecleucel (tisa-cel) in patients with relapsed follicular lymphoma (NCT03568461). Dr Riedell emphasizes the encouraging results of the trial with a favourable complete response rate observed. However, follow-up is ideal to understand the long-term outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Peter A. Riedell, MD, reports research support/funding from Celgene/BMS, Kite Pharma, Inc./Gilead, MorphoSys, Calibr, Xencor, Tessa Therapeutics, and Novartis Pharmaceuticals Corporation; speaker’s bureau from Kite Pharma, Inc./Gilead and Bayer; consultancy on advisory boards from Verastem Oncology, Novartis Pharmaceuticals Corporation, Celgene/BMS, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, and Bayer; honoraria from Novartis Pharmaceuticals Corporation.
